Future prospective trials will have to elucidate whether serum Ang-2 concentrations alone or in combination with serum cystatin C concentrations might improve the (early) diagnosis of kidney damage or serve as a prognostic marker for chronic renal failure. This evidence concerns the gene CST3 and chronic kidney disease.